理解抗TNF治疗失败:血清三碘甲状腺原氨酸与甲状腺素比值(T3/T4)能否预测活动性腔型克罗恩病初治患者的抗TNF治疗结局?
结果显示该比值较低与女性、使用皮质激素及疾病活动相关,且与第14周原发无应答独立相关(OR 0.51,95%CI 0.31-0.85,p=0.009),但与第54周未缓解及粪钙卫蛋白变化无关。
要点
- 基线fT3/fT4比值较低与女性、使用皮质激素及更严重炎症相关。
- fT3/fT4比值与第14周原发无应答独立相关(OR 0.51,95%CI 0.31-0.85,p=0.009)。
- 该比值未预测第54周未缓解或粪钙卫蛋白变化。
核心结论
- 较低的基线血清fT3/fT4比值与女性、使用皮质激素及疾病活动度相关,可预测第14周抗TNF治疗的原发无应答,但不能预测第54周未缓解。
研究设计与样本
- 基于PANTS研究,对未使用过生物制剂的成人活动性腔型克罗恩病患者治疗前储存血清进行甲状腺功能检测。
- 患者接受英夫利西单抗(原研427例、生物类似药122例)或阿达木单抗(448例)治疗。
主要发现
- 基线fT3/fT4比值中位数[IQR]女性低于男性(0.30[0.27-0.34] vs 0.32[0.28-0.36],p<0.001)。
- 使用皮质激素者fT3/fT4比值低于未使用者(0.28[0.25-0.33] vs 0.32[0.29-0.36],p<0.001)。
- 多变量logistic回归显示fT3/fT4比值与第14周原发无应答独立相关(OR 0.51,95%CI 0.31-0.85,p=0.009)。
- fT3/fT4比值与第54周未缓解或粪钙卫蛋白浓度变化无关。
- 预测原发无应答的最佳阈值为0.31(AUC 0.57[95%CI 0.54-0.61],敏感度0.62[95%CI 0.41-0.74],特异度0.53[95%CI 0.42-0.73])。
关键数值与推荐
- fT3/fT4比值预测第14周原发无应答的OR为0.51(95%CI 0.31-0.85,p=0.009)。
- 最佳阈值为0.31,AUC 0.57(95%CI 0.54-0.61),敏感度0.62(95%CI 0.41-0.74),特异度0.53(95%CI 0.42-0.73)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During illness, adaptations of the hypothalamic-pituitary-thyroid axis reduce energy expenditure, protein catabolism and modulate immune responses to promote survival. Lower serum free triiodothyronine-to-thyroxine (fT3/fT4) ratio has been linked to non-response to treatment in a range of diseases, including in biologic-treated patients with inflammatory bowel disease. AIM: To assess whether baseline serum fT3/fT4 ratio predicted primary non-response (PNR) and non-remission to infliximab and adalimumab in patients with Crohn's disease METHODS: Thyroid function tests were undertaken in stored serum from biologic-naïve adult patients with active luminal Crohn's disease immediately prior to treatment with infliximab (427 originator; 122 biosimilar) or adalimumab (448) in the Personalised Anti-TNF Therapy in Crohn's Disease study (PANTS). RESULTS: Baseline median [IQR] fT3/fT4 ratios were lower in women than men (0.30 [0.27-0.34] vs 0.32 [0.28-0.36], p < 0.001), in patients with more severe inflammatory disease, and in patients receiving corticosteroids (0.28 [0.25-0.33] vs. 0.32 [0.29-0.36], p < 0.001). Multivariable logistic regression analysis demonstrated that fT3/fT4 ratio was independently associated with PNR at week 14 (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.31-0.85, p = 0.009), but not non-remission or changes in faecal calprotectin concentrations at week 54. The optimal threshold to determine PNR was 0.31 (area under the curve 0.57 [95% CI 0.54-0.61], sensitivity 0.62 [95% CI 0.41-0.74], and specificity 0.53 [95% CI 0.42-0.73]). CONCLUSIONS: Lower baseline serum fT3/fT4 ratio was associated with female sex, corticosteroid use and disease activity. It predicted PNR to anti-TNF treatment at week 14, but not non-remission at week 54.
引用
- Lin S, Chanchlani N, Carbery I, et al. Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease? Aliment Pharmacol Ther. 2022. PMID: 35768996. doi:10.1111/apt.17089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。